about
Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control StudiesTowards the genetic basis of cerebral venous thrombosis-the BEAST Consortium: a study protocol.Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.Risk factors for venous and arterial thrombosisActivation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk.New approaches for measuring coagulation.The hemostatic system through aging and menopause.Thrombophilic states.Cerebral thrombosis and myeloproliferative neoplasms.Association between red cell distribution width and risk of venous thromboembolism.Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study.Hematological evaluation of acquired von Willebrand syndrome before oral surgery: Management of an unusual case.Anticoagulant treatment with rivaroxaban in severe protein S deficiency.Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly.Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study.Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users.Fibrinogen Milano XIII (Aalpha 19 Arg-->Gly): a dysfunctional variant with an amino acid substitution in the N-terminal polymerization site.Circulating microparticles and risk of venous thromboembolism.Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status.Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms.Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII.Pregnancy outcome after a first episode of cerebral vein thrombosis.Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinus-venous thrombosis.Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.Red cell distribution width and the risk of cerebral vein thrombosis: A case-control study.Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma.Psychological impact of thrombosis in the young.Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.Hemostatic abnormalities in Noonan syndrome.The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.Pulmonary embolism in elderly patients: prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality.Coagulation testing before epidural analgesia at delivery: cost analysis.Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels.Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome.The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both.Risk factors for postpartum hemorrhage in a cohort of 6011 Italian women.Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.The JAK2 V617F mutation in patients with cerebral venous thrombosis.
P50
Q28607612-3CEEAC69-8308-4607-93B3-6A14575AA7A4Q30490386-BBC4FD00-873D-484E-8D6B-EBE99F94F1FFQ33381231-8F242E49-3EC3-4AD9-8D0E-72DD7FDB021DQ34988616-C456C28A-4C47-4760-936F-BFA47AB0DB72Q35658142-8B51C745-5D0B-4D44-9A64-8949A4166977Q36473061-6442B26F-712C-48D4-9FBC-CFC65C09B371Q37610388-AFD75548-4889-4FA6-A93E-0EF1289BACF0Q38173538-3409B01C-F904-4416-8CE9-4C17EE72ED7CQ38248785-6201E70F-8C1B-488C-A852-1177A61C3B34Q40684733-C3BA1396-BF99-410C-96ED-9D995EA690A3Q40819096-0B97A5E5-034E-4C9D-A671-F5C3C8D71882Q42143381-38EDFCF8-4507-42AB-B4C7-9226A06B5AB0Q43569902-D8AF72AF-9605-4053-AB91-47BB20FC2415Q43646517-73FD2816-80D4-4AF5-9F02-F6F59BB2A5E3Q44563073-DB785B0A-FFFD-4FD1-A2CC-3A5C4BC7798DQ44794623-38D4C04D-3C36-40E6-801F-F4E303FCCDC8Q44933363-EE6E8845-0C05-4427-92EB-009A9D01D244Q45343578-56C8FF0E-2F4C-4FC5-ABE6-6683D1D7D273Q45713731-C8587337-DE77-4AD3-AEE4-8493884E0668Q45855734-90889220-550D-4C75-A32B-9DA6DEA8FAFEQ45856951-3EAD77F7-733E-406C-880D-9FBC7C29012CQ45858020-08DFC15A-7DC3-4717-8794-3589319FDE3EQ45859145-286507F2-CE76-45AF-B5C5-5F4B7583E47DQ45861333-C1D31DD8-2A23-4C6A-B4C6-767B5E0F5167Q45861683-502E7FD8-F320-4A73-B138-A4BA11628F04Q45863215-EB1F42DE-9227-47F8-87A6-AFA7466EBAD3Q45863890-0CE78B8E-1F95-4610-A043-A6E609ACA642Q45864132-EFA9E557-4F27-4834-BE3F-1691005DC447Q45864401-4D11FF44-06C2-4B15-9DF3-93A7D3E22E40Q45864717-8E4E336A-D662-46D6-84AB-12D422EB2F6CQ45866195-2BB9674F-F609-4A71-88AE-F80CAC88CC66Q45868724-39DBCC03-A782-4784-A179-2BF840339895Q45870427-449A49CC-7EBA-4DF2-AAAD-C02BB4146296Q45872338-5E10249C-1AD5-464A-B4D4-6969234C4DAFQ45874156-5219149F-C287-4544-A4BC-A40249559ACFQ45874287-A859CDFC-9D23-4231-ADD0-879D4E282087Q45876700-E7B5AD83-DD2B-40B3-8186-9375FA67D229Q45877099-36986041-FBD2-428E-9BA1-C669DF5EFA5EQ45877995-82351E35-1071-4A20-835E-5D6BCCD97F5BQ45878282-63A41E9E-D690-44F6-BE94-6BCCE00155FF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Bucciarelli
@ast
Paolo Bucciarelli
@en
Paolo Bucciarelli
@es
Paolo Bucciarelli
@nl
Paolo Bucciarelli
@sl
type
label
Paolo Bucciarelli
@ast
Paolo Bucciarelli
@en
Paolo Bucciarelli
@es
Paolo Bucciarelli
@nl
Paolo Bucciarelli
@sl
prefLabel
Paolo Bucciarelli
@ast
Paolo Bucciarelli
@en
Paolo Bucciarelli
@es
Paolo Bucciarelli
@nl
Paolo Bucciarelli
@sl
P1053
J-1907-2015
P106
P21
P31
P3829
P496
0000-0003-0877-365X